Population-specific association between ABCG2 variants and tophaceous disease in people with gout

Table 4 ABCG2 analysis according to ancestry, with adjustment for potential confounders

ABCG2 variant	Risk allele		All participants (n = 1778)		Non-Polynesian ancestry (n = 927)		Māori or Pacific ancestry (n = 851)		Eastern Polynesian ancestry (n = 464)		Western Polynesian ancestry (n = 387)
ABCG2 variant	Risk allele		Allelic OR (95% CI)	P	Allelic OR (95% CI)	P	Allelic OR (95% CI)	P	Allelic OR (95% CI)	P	Allelic OR (95% CI)	P
rs2231142	T	Unadjusted	1.24 (1.02–1.51)	0.033	0.97 (0.73–1.28)	0.80	1.50 (1.14–1.99)	0.004	1.28 (0.84–1.96)	0.25	1.71 (1.07–2.72)	0.017
		Adjusted for age, sex, ancestry^a	1.30 (1.06–1.58)	0.012	0.99 (0.74–1.31)	0.93	1.51 (1.14–2.01)	0.004	1.24 (0.81–1.91)	0.32	1.79 (1.12–2.87)	0.015
		Adjusted for age, sex, ancestry^a, highest recorded urate, serum creatinine and disease duration	1.16 (0.94–1.43)	0.17	0.97 (0.72–1.30)	0.83	1.37 (1.01–1.85)	0.042	0.91 (0.57–1.45)	0.70	1.66 (1.01–2.75)	0.048
rs10011796	T	Unadjusted	1.33 (1.01–1.74)	0.040	1.16 (0.81–1.66)	0.41	1.44 (0.94–2.20)	0.093	0.87 (0.52–1.46)	0.60	3.76 (1.61–8.77)	0.002
		Adjusted for age, sex, ancestry^a	1.31 (0.997–1.72)	0.052	1.18 (0.83–1.69)	0.36	1.45 (0.95–2.22)	0.089	0.87 (0.52–1.47)	0.61	3.75 (1.60–8.77)	0.002
		Adjusted for age, sex, ancestry^a, highest recorded urate, serum creatinine and disease duration	1.25 (0.94–1.65)	0.13	1.12 (0.77–1.62)	0.55	1.39 (0.88–2.18)	0.16	0.82 (0.47–1.43)	0.49	3.23 (1.35–7.76)	0.009

ISSN: 1478-6362